GlassScriptPhysician profile
Fadi F Estephan
NPI 1013987924
$48,403.12
in general payments reported to CMS, 2019-2025
47 companies · $6,377 in 2025
The $6,377 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $4,447 · 2021: $9,011 · 2022: $249 · 2023: $15K · 2024: $2,189 · 2025: $6,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Travel and Lodging: $2,757 · Honoraria: $2,625 · Food and Beverage: $2,543 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,438 · Education: $57.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,318.00 |
| Travel and Lodging | $2,757.35 |
| Honoraria | $2,625.00 |
| Food and Beverage | $2,543.09 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,437.50 |
| Education | $57.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $7,137.57 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $7,087.40 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Exelixis INC. | $5,441.09 | 2019-2025 | Cabometyx |
| Gilead Sciences, INC. | $4,436.74 | 2021-2025 | Trodelvy |
| Incyte Corporation | $3,797.16 | 2023-2025 | Monjuvi |
| Clovis Oncology, INC. | $3,415.18 | 2019 | |
| Karyopharm Therapeutics INC. | $3,398.80 | 2020-2022 | |
| Janssen Biotech, INC. | $3,100.19 | 2019-2025 | Imbruvica, Darzalex, Talvey |
| Celgene Corporation | $1,584.04 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Beigene USA, INC. | $1,500.00 | 2023 | Brukinsa |
| Cti Biopharma Corp. | $1,437.50 | 2023 | Vonjo |
| Epizyme, INC. | $1,250.00 | 2021 | |
| Geron Corporation | $1,200.00 | 2025 | Rytelo |
| Pfizer INC. | $504.99 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $372.70 | 2019-2025 | Opdivo, Opdualag |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $342.30 | 2019-2025 | |
| Abbvie INC. | $247.46 | 2023-2025 | |
| Astellas Pharma US INC | $211.59 | 2019-2025 | Vyloy, Xtandi, Xospata |
| Array Biopharma INC | $184.69 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Emd Serono, INC. | $166.45 | 2022-2025 | Bavencio |
| Daiichi Sankyo INC. | $142.49 | 2019-2025 | Enhertu |
| Jazz Pharmaceuticals INC. | $127.05 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.25 | 2019 | |
| Amgen INC. | $101.33 | 2019-2020 | |
| Comsort, INC | $100.00 | 2019 | |
| Merck Sharp & Dohme LLC | $85.99 | 2019-2020 | |
| Genentech USA, INC. | $80.40 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Eisai INC. | $67.14 | 2019-2025 | |
| Glaxosmithkline, LLC. | $59.73 | 2022-2023 | Zejula, Jemperli |
| Nevro Corp. | $48.34 | 2024 | Senza |
| Kite Pharma, INC. | $32.81 | 2022-2023 | |
| Genzyme Corporation | $30.17 | 2019 | |
| Recordati_rare_diseases_inc. | $24.44 | 2025 | Enjaymo |
| Genmab U.S., INC. | $23.90 | 2025 | Epkinly |
| Tersera Therapeutics LLC | $22.15 | 2025 | Zoladex |
| Sobi, INC | $19.77 | 2025 | |
| Kyowa Kirin, INC. | $19.52 | 2024 | Poteligeo |
| Regeneron Healthcare Solutions, INC. | $19.40 | 2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $17.50 | 2025 | Ninlaro |
| Agios Pharmaceuticals, INC. | $16.42 | 2023 | Pyrukynd |
| Ipsen Biopharmaceuticals, INC | $16.14 | 2025 | Onivyde |
| Springworks Therapeutics, INC. | $15.77 | 2024 | Ogsiveo |
| Mirati Therapeutics, INC. | $14.43 | 2024 | Krazati |
| Sun Pharmaceutical Industries INC. | $13.08 | 2019 | |
| Verastem, INC. | $13.05 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Estephan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.